SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 7.6% Passive Stake in Regeneron Pharmaceuticals
Beneficial Ownership Statement
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 8,188,770.17 shares of Regeneron Pharmaceuticals Inc. common stock.
- This ownership represents 7.6% of the total outstanding common stock of Regeneron Pharmaceuticals Inc.
- FMR LLC holds sole voting power over 7,823,952.35 shares and sole dispositive power over 8,188,770.17 shares.
- Abigail P. Johnson holds sole dispositive power over 8,188,770.17 shares.
- The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC (which beneficially owns 5% or greater of the outstanding shares), contribute to this beneficial ownership.
Sentiment
Score: 7
Explanation: The filing is neutral to positive, indicating a stable, significant passive investment by a major institutional holder. It doesn't contain negative news or operational issues, but also no new positive developments beyond the continued holding.
Positives
- A significant institutional investor, FMR LLC, maintains a substantial passive stake, indicating continued confidence in Regeneron Pharmaceuticals Inc.
- The filing confirms the stake is held for ordinary course of business, not for control influence, suggesting stability in the ownership structure.
Future Outlook
NA
Industry Context
This filing reflects a significant passive investment by a major asset manager, FMR LLC, in a leading biotechnology company, Regeneron Pharmaceuticals. Such disclosures are routine for large institutional holders and do not typically signal a change in industry trends but rather a continued investment in established players within the pharmaceutical sector.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be viewed positively as a vote of confidence from a major investor.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-11 | Filing date of the Schedule 13G Amendment No. 6. |
Recommendation
holdKeywords
Regeneron Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.